China Biologic Products to Present at CCG IR's China Rising Conference and Oppenheimer's China Dragon Call Conference in New York
May 15, 2009
TAIAN CITY, Shandong, China, May 15 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (OTC: CBPO) (BULLETIN BOARD: CBPO) (''China Biologic'' or the ''Company''), one of the leading plasma-based pharmaceutical companies in the People's Republic of China (''PRC''), today announced that the Company's management will present at the upcoming China Rising Conference hosted by CCG Investor Relations in New York, NY on May 18, 2009 and the 3rd Annual China Dragon Call Conference hosted by Oppenheimer & Co. Inc. on May 19 to 21, 2009.
The date, time and location of China Biologic' presentation at the China Rising Conference is as follows:
Date: Monday, May 18, 2009 Time: 10:30 a.m. to 11:00 a.m. Eastern Time Presenter: Tristan Kuo, Chief Financial Officer of China Biologic Venue: The Yale Club 50 Vanderbilt Avenue New York, NY 10017 Webcast: http://www.chinarisingconference.com/webcast.html
A replay of the webcast will be available for up to one year following the presentation using the same link.
The China Rising Investment Conference hosted by CCG Investor Relations will provide over 250 fund managers and investors access to senior management of a wide range of Chinese growth companies in sectors including consumer staples, agriculture, pharmaceuticals, infrastructure, information technology, advanced materials, capital goods, and alternative energy. The conference will include over 30 US-listed Chinese companies and a number of private companies.
Interested parties and investors may find more information for the conference by visiting the website at http://www.chinarisingconference.com/ .
The date, time and location of China Biologic's presentation at the Oppenheimer 3rd Annual China Dragon Call Conference are as follows:
Date: Tuesday, May 19, 2009 Time: 10:15 p.m. to 10:45 p.m. Eastern Time Presenter: Tristan Kuo, Chief Financial Officer of China Biologic Venue: 300 Madison Avenue New York City
The China Dragon Call Conference hosted by Oppenheimer & Co. Inc. will provide intimate access to senior management of leading Chinese companies. These discussions will give investors an ability to analyze secular trends, to identify emerging opportunities and to gather insight into China's investment outlook.
All conferences are for institutional clients of Oppenheimer & Co. Inc. and are by invitation only. For more information, please contact Oppenheimer & Co. Inc. institutional sales representative.
About China Biologic Products, Inc.
China Biologic Products, Inc. (the ''Company''), through its indirect majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., and equity investments in Xi'an Huitian Blood Products Co., Ltd. and Chongqing Dalin Biologic Technologies Co., Ltd. is currently the largest non-state-owned plasma-based biopharmaceutical company approved by the Chinese government. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company's blood products are irreplaceable in the application of medical emergencies, and prevention and treatment for various diseases. It sells its plasma-based biopharmaceutical products to hospitals and other healthcare facilities in China.
Safe Harbor Statement
This release may contain certain ''forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiary companies. All statements, other than statements of historical fact included herein are ''forward-looking statements," including statements regarding: the ability of the Company to achieve its commercial objectives; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," ''expects'' or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov/). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
For more information, please contact: Company Contact: Mr. Y. Tristan Kuo Chief Financial Officer China Biologic Products, Inc. Tel: +86-538-6202206 Email: IR@chinabiologic.com Web: http://www.chinabiologic.com/ Investor Relations Contact: Mr. Crocker Coulson, President CCG Investor Relations Tel: +1-646-213-1915 (NY office) or Mr. Gary Chin Tel: +1-646-213-1909 Email: firstname.lastname@example.org Web: http://www.ccgirasia.com/
SOURCE: China Biologic Products, Inc.
CONTACT: Y. Tristan Kuo, Chief Financial Officer at China Biologic
Products, Inc. at +86-538-6202206 or IR@chinabiologic.com; Investor Relations
Contact: Crocker Coulson, President, CCG Investor Relations at +1-646-213-1915
(NY office) or email@example.com or Gary Chin at +1-646-213-1909